| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 10/26/2004 | CA2132514C Antiproliferative quinazolines |
| 10/26/2004 | CA2127411C Tricyclic derivatives |
| 10/26/2004 | CA2111283C Process for preparation of indolopyrrolocarbazole derivatives |
| 10/26/2004 | CA2023811C Process and intermediates for preparing compounds having a disubstituted acetylene moiety and retinoic acid-like biological activity |
| 10/21/2004 | WO2004090541A1 METHOD OF SCREENING DRUG WITH THE USE OF 67 kDa LAMININ RECEPTOR AND DRUG OBTAINED THEREBY |
| 10/21/2004 | WO2004089992A1 Modified acacia and use thereof |
| 10/21/2004 | WO2004089989A1 Cancerous disease modifying antibodies |
| 10/21/2004 | WO2004089984A1 Antigen recognizing antibody |
| 10/21/2004 | WO2004089976A1 Method of treatment |
| 10/21/2004 | WO2004089964A1 Lipid-regulating agent and use thereof |
| 10/21/2004 | WO2004089962A2 New carbamoyl-and thiocarbamoyl-phosphonates and pharmaceutical compositions comprising them |
| 10/21/2004 | WO2004089955A1 Pyrimido compounds |
| 10/21/2004 | WO2004089913A1 Aminopyrimidine derivatives and their medical use |
| 10/21/2004 | WO2004089882A2 Aromatic sulfonamides as peroxynitrite-rearrangement catalysts |
| 10/21/2004 | WO2004089419A1 Lipid membrane structure containing anti-mt-mmp monoclonal antibody |
| 10/21/2004 | WO2004089415A2 COMBINATIONS OF AN 11β-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITOR AND A GLUCOCORTICOID RECEPTOR AGONIST |
| 10/21/2004 | WO2004089413A1 Nucleotide and cellular vaccine composition |
| 10/21/2004 | WO2004089399A1 Novel uses of rfrp and ot7t022 |
| 10/21/2004 | WO2004089356A2 Targeted bone marrow protection agents |
| 10/21/2004 | WO2004089282A2 Therapeutic polypeptides, nucleic acids encoding same, and methods of use |
| 10/21/2004 | WO2004073650A3 Peptidomimetic inhibitors of stat3 activity and their medical uses |
| 10/21/2004 | WO2004073592A3 Semi-solid immediate-release oral formulations comprising an anticancer hydrophobic agent, a polyglycolised glyceride and a hydrophilic carrier |
| 10/21/2004 | WO2004073375A8 Podophyllotoxin derivatives as antitumor agents |
| 10/21/2004 | WO2004071505A3 Radiolabelled d-amino acids for use in diagnosis with spect and pet and systemic radionuclide therapy |
| 10/21/2004 | WO2004054968A3 25-so2-substituted analogs of 1alpha, 25-dihydroxyvitamin d3 (calcitriol) |
| 10/21/2004 | WO2004043428A3 Buccal, polar and non-polar spray or capsule containing drugs for treating pain |
| 10/21/2004 | WO2004024062A3 Platinum complexes as antitumor agents in combination with biochemical modulation |
| 10/21/2004 | WO2004009609A3 Nucleoside compounds and their use for treating cancer and diseases associated with somatic mutations |
| 10/21/2004 | WO2003096980A3 Bicyclic modulators of androgen receptor function |
| 10/21/2004 | WO2003093793A3 Binary or polynary targeting and uses thereof |
| 10/21/2004 | WO2003062241A8 Fused heterocyclic succinimidecompounds and analogs thereof, modulators of nuclear hormone receptor function |
| 10/21/2004 | WO2003043631A3 Method for identification of tumor targeting enzymes |
| 10/21/2004 | WO2003026490A3 Methods and compositions for prevention, diagnosis, and treatment of cancer using bispecific molecules |
| 10/21/2004 | WO2003024392A3 Compositions and methods for the diagnosis and treatment of tumor |
| 10/21/2004 | WO2003000014A3 Spherical protein particles and methods of making and using them |
| 10/21/2004 | WO1995027066A9 Dna encoding ubiquitin conjugating enzymes |
| 10/21/2004 | US20040210080 3-(oxo, oxime, hydrazone, or alkylidene)-fluorene derivatives; can be synergistically combined with other anticarcinogenic, anticholesterol, anxiolytic agents, antidepressants or enzyme inhibitors; bone disorders |
| 10/21/2004 | US20040210052 Efficient synthesis of 5-heteroatom-containing-pyrazoles |
| 10/21/2004 | US20040210042 Polypeptides relating to signal transfer of advanced glycation end product receptor |
| 10/21/2004 | US20040210040 Monoclonal antibodies for use in the prevention and treatment of cell proliferative and skin disorders; immunotherapy; antitumor agents |
| 10/21/2004 | US20040209942 treating cancer and apoptosis-associated disorders using cell cycle checkpoint activation modulators; also screening for the modulators |
| 10/21/2004 | US20040209938 Novel 1,3-dihydro-2H-indol-2one derivatives, process for preparing them and pharmaceutical compositions containing them |
| 10/21/2004 | US20040209935 Pyrazole-derived kinase inhibitors and uses thereof |
| 10/21/2004 | US20040209934 Protein phosphate inhibitors |
| 10/21/2004 | US20040209933 containing a p-[4-(1H-[1,2,3]triazolyl)butyl]phenoxymethyl group, e.g., 1-(4-{4-[2-(2-Benzo[1,3]dioxol-5-yl-vinyl)-oxazol-4-ylmethoxy]-phenyl}-butyl)-1H-[1,2,3]triazole or salt; anticancer agents |
| 10/21/2004 | US20040209922 Pyridine matrix metalloproteinase inhibitors |
| 10/21/2004 | US20040209914 Aromatic sulfone hydroxamic acids and their use as protease inhibitors |
| 10/21/2004 | US20040209908 New derivatives of hydantoins, thiohydantoins, pyrimidinediones and thioxopyrimidinones, their preparation processes and their use as medicaments |
| 10/21/2004 | US20040209905 Quinoline derivatives and quinazoline derivatives |
| 10/21/2004 | US20040209901 substituted 2,4,8-trisubstituted-8H-pyrido[2,3-d]pyrimidin-7-one compounds, e.g., 8-(2,6-Difluoro-phenyl)-4-(4-fluoro-2-methyl-phenyl)-2-(2-hydroxy-1-hydroxymethyl-ethylamino)-8H-pyrido[2,3-d]pyrimidin-7-one; CSBP/p38 kinase inhibitors. |
| 10/21/2004 | US20040209899 A2B adenosine receptor antagonists |
| 10/21/2004 | US20040209895 inhibit cyclin-dependent kinases and VEGF-receptor tyrosine kinases |
| 10/21/2004 | US20040209894 e.g., 1-(4-chloroanilino)-4-[2-(pyridin-3-yl)-ethyl]-isoquinoline and 5-[4-(tert-butyl)-anilino]-8-[(6-methoxy-pyridin-3-yl)-methyl]-[1,6]naphthyridine |
| 10/21/2004 | US20040209892 Heterocyclic compounds and methods of use |
| 10/21/2004 | US20040209883 Nitrogen-containing heterocyclic compounds and their use as raf inhibitors |
| 10/21/2004 | US20040209879 Piperidinyl derivates as modulators of chemokine receptor activity |
| 10/21/2004 | US20040209874 Hydantoins and related heterocycles as inhibitors of matrix metalloproteinases and/or TNF-alpha converting enzyme (TACE) |
| 10/21/2004 | US20040209868 Substituted indoles |
| 10/21/2004 | US20040209866 1,8 Naphthyridine derivatives and their use to treat diabetes and related disorders |
| 10/21/2004 | US20040209856 Oral pharmaceutical products containing 17beta-estradiol-3-lower alkanoate, method of administering the same and process of preparation |
| 10/21/2004 | US20040209848 Administering to a patient (11 alpha , 15 alpha , 13E)-9-oxo-11,15-dihydroxy- 16-(3-methoxymethylphenyl)-17, 18, 19, 20-tetranor-5-thiaprost-13-enoic acid methyl ester, or cyclodextrin clathrate for treating osteoporosis |
| 10/21/2004 | US20040209845 Novel styrylacrylonitrile compounds which are useful in treating a variety of cell proliferative disorders such as cancer and specifically acute lymphoblastic leukemia; (E,E)-2-(benzylamido)-3-styrylacrylonitrile for example |
| 10/21/2004 | US20040209834 mouse double minute (MDM); determining the mdm2-dependent growth activity of a cell by introducing vectors for expressing a p53 polypeptide or fragment into the cell, and measuring the growth of the cell |
| 10/21/2004 | US20040209832 RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA) |
| 10/21/2004 | US20040209828 Solvent-free anthracycline derivatives |
| 10/21/2004 | US20040209799 comprises inhibitors (cytokines) of janus kinases (JAK)/signal transducers and activators of transcription (STAT) other than debromohymenialdisine and hymensialdisine; gene expression inhibition; bioassay, immunoassay, drug screening; for treatment of degenerative joint diseases such as osteoarthritis |
| 10/21/2004 | US20040209798 biodrugs for treatment of lung cancer, glioma, anorexia, hypothyroidism, hyperaldosteronism, H. pylori proliferation, acromegaly, restenosis, Crohn's disease, systemic sclerosis, external and internal pancreatic pseudocysts and ascites |
| 10/21/2004 | US20040209296 Using transcription factor inhibitors and human leukocyte antigen antibodies to prevent and treatcell proliferfative disorders; genetic vaccines and antitumor agents |
| 10/21/2004 | US20040209264 Comprises nucleotide sequences coding daugther of legless protein for use in identifying modulator for tissue regeneration and repair and the treatment of blood disorders |
| 10/21/2004 | US20040208944 Compositions and methods against inflammatory processes |
| 10/21/2004 | US20040208935 Small particle liposome aerosols for delivery of anti-cancer drugs |
| 10/21/2004 | US20040208924 active pharmaceutical ingredient is for example [(2S)-Sulfanyl-5-[(N,N-dimethylamino)acetyl]aminopentanoyl-L-leucyl-L-tert-leucine N-methylamide; bonding strength, stability |
| 10/21/2004 | US20040208867 Mutant protein with amino acid sequence that is substituted, deleted, inserted or transposed; 3'-phosphoadenosine5'-phosphosulfate; gene expression; medical diagnosis |
| 10/21/2004 | US20040208859 Bile acid absorbent/adsorbent |
| 10/21/2004 | US20040208851 Immunization by inoculation of DNA transcription unit |
| 10/21/2004 | US20040208844 Products and drug delivery vehicles |
| 10/21/2004 | US20040208821 Administering a soft tissue targeting complex of thorium-227 and a complexing agent, in vivo nuclear decay to radium-223; drug targets for treating cancer |
| 10/21/2004 | CA2528001A1 Lipid membrane structure containing anti-mt-mmp monoclonal antibody |
| 10/21/2004 | CA2523186A1 Method of screening drug with the use of 67 kda laminin receptor and drug obtained thereby |
| 10/21/2004 | CA2522456A1 Nucleotide and cellular vaccine composition |
| 10/21/2004 | CA2521692A1 Modified acacia and use thereof |
| 10/21/2004 | CA2521653A1 Aromatic sulfonamides as peroxynitrite-rearrangement catalysts |
| 10/21/2004 | CA2521384A1 New carbamoyl-and thiocarbamoyl-phosphonates and pharmaceutical compositions comprising them |
| 10/21/2004 | CA2521375A1 Cancerous disease modifying antibodies |
| 10/21/2004 | CA2521340A1 Aminopyrimidine derivatives and their medical use |
| 10/21/2004 | CA2521124A1 Pyrimido compounds |
| 10/21/2004 | CA2501222A1 Antibody recognizing antigen |
| 10/20/2004 | EP1469084A2 Polymorphisms in the human KDR gene |
| 10/20/2004 | EP1469077A1 Cell-specific expression/replication vector |
| 10/20/2004 | EP1469075A1 Gene-therapy for solid tumors, papillomas and warts |
| 10/20/2004 | EP1469065A1 Composition of antibody specifically binding to cd20 |
| 10/20/2004 | EP1469009A2 Compositions and methods for non-parenteral delivery of oligonucleotides |
| 10/20/2004 | EP1468991A1 Imides as PDE III, PDE IV and TNF inhibitors |
| 10/20/2004 | EP1468698A2 Human quinone reductase 2 conjugates for adept and gdept |
| 10/20/2004 | EP1468695A1 Methods and compositions useful for inhibition of angiogenesis |
| 10/20/2004 | EP1468688A2 Benzoazine mono-N-oxides and benzoazine 1,4 dioxides and compositions therefrom for the therapeutic use in cancer treatments |
| 10/20/2004 | EP1468687A1 Compounds for the treatment of cancer |
| 10/20/2004 | EP1468118A2 Methods and compositions for treating cancer |
| 10/20/2004 | EP1468110A2 Molecular signatures of commonly fatal carcinomas |
| 10/20/2004 | EP1468097A2 METHODS OF GENERATING MULTISPECIFIC, MULTIVALENT AGENTS FROM V sb H /sb AND V sb L /sb DOMAINS |